Breakthroughs in Solubility Optimization for Pediatric Drug Formulations
DOI:
https://doi.org/10.32947/ajps.v25i5.1279Keywords:
Pediatric population, Techniques, Dosage form, Excipients, SolubilityAbstract
Formulating drugs for pediatric patients is more complex than for adults due to the diversity within this group. Solubility of active pharmaceutical ingredients (APIs) presents specific challenges, since children have unique physiological traits—smaller stomach volume and immature digestive systems—that affect absorption, metabolism, and overall drug effectiveness.
Oral formulations must consider drug sensitivity, swallowing difficulties, and compliance. Taste, ease of administration, and patient acceptance strongly influence therapeutic outcomes and safety. Ensuring children take medication as directed is often as important as the formulation itself.
To address these issues, solubility enhancement technologies have advanced
References
1- Malkawi WA, AlRafayah E, AlHazabreh M, AbuLaila S, Al-Ghananeem AM. Formulation challenges and strategies to develop pediatric dosage forms. Children. 2022 Apr 1;9(4).Pp:488.
2-Sura Zuhair M, Nora Zawar Y, Zeina Dawood S.Types of Attractive Dosage Forms for Primary School Students and Associated Factors in Baghdad/ Iraq.Al Mustansiriyah Journal of Pharmaceutical Sciences.2022.20(4).Pp:13-22.
3-Lopez FL, Ernest TB, Tuleu C, Gul MO.Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.Expert Opin Drug Deliv.2015.12(11).Pp:1727-40.
4-Dille MJ, Hattrem MN, Draget KI.Soft, chewable gelatin-based pharmaceutical oral formulations: a technical approach.Pharm Dev Technol.2018.23(5).Pp:504-11.
5-Rose K, Van den Anker JN. Guide to paediatric drug development and clinical research: Karger Medical and Scientific Publishers; 2010.
6-Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD.Pediatric information in drug product labeling.JAMA.2012.307(18).Pp:1914-5.
7-Denora N, Lopalco A. Paediatric Formulation: Design and Development: MDPI; 2021.
8- Jacqz-Aigrain E. Drug policy in Europe: research and funding in neonates: current challenges, future perspectives, new opportunities. Early human development. 2011 Mar 1;87:S27-30.
9-Serrano DR, Kara A, Yuste I, Luciano FC, Ongoren B, Anaya BJ, et al.3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals.Pharmaceutics.2023.15(2).Pp:
10-Meyers RS.The Past, Present, and Future of Oral Dosage Forms for Children.J Pediatr Pharmacol Ther.2024.29(1).Pp:22-31.
11-Nunn T, Williams J.Formulation of medicines for children.Br J Clin Pharmacol.2005.59(6).Pp:674-6.
12- Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Frontiers in pharmacology. 2021 Feb 19;12:618411.
13-Kim J, De Jesus O. Medication Routes of Administration: StatPearls Publishing, Treasure Island (FL); 2023.
14-Lou J, Duan H, Qin Q, Teng Z, Gan F, Zhou X, et al.Advances in Oral Drug Delivery Systems: Challenges and Opportunities.Pharmaceutics.2023.15(2).Pp:484.
15-Montgomery RK, Grand RJ. Development of the gastrointestinal tract. Pediatric Gastrointestinal and Liver Disease: Elsevier; 2011. p. 2-9. e2.
16-Mistry P, Batchelor H, project SP-U.Evidence of acceptability of oral paediatric medicines: a review.J Pharm Pharmacol.2017.69(4).Pp:361-76.
17-Ricci BM.Bridging studies in support of oral pediatric formulation development.Int J Pharm.2013.457(1).Pp:323-6.
18-Ward RM, Benjamin D, Barrett JS, Allegaert K, Portman R, Davis JM, et al.Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.Pediatr Res.2017.81(5).Pp:692-711.
19- Committee for Medicinal Products for Human Use. Guideline on pharmaceutical development of medicines for pediatric use. European Medicines Agency Scientific Guidelines. Accessed. 2018 Jul;15.
20-Sam T, Ernest TB, Walsh J, Williams JL.A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms - an application for paediatric dosage form selection.Int J Pharm.2012.435(2).Pp:115-23.
21-Natalie S, Viviane K, Ines S, Christian L, Thomas M, Jörg B.Acceptance of drug-free minitablets in young children.
22-Litalien C, Berube S, Tuleu C, Gilpin A, Landry EK, Valentin M, et al.From paediatric formulations development to access: Advances made and remaining challenges.Br J Clin Pharmacol.2022.88(10).Pp:4349-83.
23-Litalien C, Bérubé S, Tuleu C, Gilpin A, Landry É K, Valentin M, et al.From paediatric formulations development to access: Advances made and remaining challenges.Br J Clin Pharmacol.2022.88(10).Pp:4349-83.
24-Kristensen HG.WHO guideline development of paediatric medicines: points to consider in pharmaceutical development.Int J Pharm.2012.435(2).Pp:134-5.
25-Krause J, Breitkreutz J.Improving Drug Delivery in Paediatric Medicine.Pharmaceutical Medicine.2008.22(1).Pp:41-50.
26-Galande AD, Khurana NA, Mutalik SJJoAPS.Pediatric dosage forms-challenges and recent developments: A critical review.2020.10(7).Pp:155-66.
27- Committee for Medicinal Products for Human Use. Formulations of choice for the paediatric population. European Medicines Agency. 2005.
28-Venables R, Stirling H, Batchelor H, Marriott J.Problems with oral formulations prescribed to children: a focus group study of healthcare professionals.Int J Clin Pharm.2015.37(6).Pp:1057-67.
29-Malkawi WA, AlRafayah E, AlHazabreh M, AbuLaila S, Al-Ghananeem AM.Formulation Challenges and Strategies to Develop Pediatric Dosage Forms.Children (Basel).2022.9(4).Pp:488.
30- Jacqz-Aigrain E. Drug policy in Europe: research and funding in neonates: current challenges, future perspectives, new opportunities. Early human development. 2011 Mar 1;87:S27-30.
31-Broussard L.Small size, big risk: preventing neonatal and pediatric medication errors.Nurs Womens Health.2010.14(5).Pp:405-8.
32-Wening K, Breitkreutz J.Oral drug delivery in personalized medicine: unmet needs and novel approaches.Int J Pharm.2011.404(1-2).Pp:1-9.
33-Donnell C, Nunn T.How to manipulate drugs so they can be given to children.Nurs Child Young People.2011.23(4).Pp:6-7.
34-Rei Bolislis W, Bejeuhr G, Benzaghou F, Corriol-Rohou S, Herrero-Martinez E, Hildebrand H, et al.Optimizing Pediatric Medicine Developments in the European Union Through Pragmatic Approaches.Clin Pharmacol Ther.2021.110(4).Pp:871-9.
35-Rosen Y, Gurman P, Elman N. Navigating the FDA Regulatory Processes: An Integrated Clinical and Engineering Approach: CRC Press; 2025.
36-Walsh J, Bickmann D, Breitkreutz J, Chariot-Goulet M, European Paediatric Formulation I.Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments.Int J Pharm.2011.415(1-2).Pp:221-31.
37-Batchelor HK, Marriott JF.Formulations for children: problems and solutions.Br J Clin Pharmacol.2015.79(3).Pp:405-18.
38- Kapoor DU, Garg R, Gaur M, Patel MB, Minglani VV, Prajapati BG, Huanbutta K, Sangnim T, Sriamornsak P. Pediatric drug delivery challenges: enhancing compliance through age-appropriate formulations and safety measures. Journal of Drug Delivery Science and Technology. 2024 Apr 26:105720.
39- Deng Y, Shen L, Yang Y, Shen J. Development of nanoparticle-based orodispersible palatable pediatric formulations. International journal of pharmaceutics. 2021 Mar 1;596:120206.
40-Lafeber I, Ruijgrok EJ, Guchelaar HJ, Schimmel KJ. 3D printing of pediatric medication: the end of bad tasting oral liquids?—a scoping review. Pharmaceutics. 2022 Feb 14;14(2):416.
41-Kennedy AR, Massey LR.Pediatric medication safety considerations for pharmacists in an adult hospital setting.Am J Health Syst Pharm.2019.76(19).Pp:1481-91.
42-Raynor DK, De Veene P, Bryant D.The Effectiveness of the Summary of Product Characteristics (SmPC) and Recommendations for Improvement.Therapeutic Innovation & Regulatory Science.2014.48(2).Pp:255-65.
43-Zuccari G, Alfei S, Marimpietri D, Iurilli V, Barabino P, Marchitto L.Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics.Pharmaceuticals (Basel).2022.15(1).Pp:108.
44 Mfoafo KA, Omidian M, Bertol CD, Omidi Y, Omidian H. Neonatal and pediatric oral drug delivery: Hopes and hurdles. International Journal of Pharmaceutics. 2021 Mar 15;597:120296.
45-Khalaf YT, Almajidi YQ, Shalan NM, Alani IH, Dayyih WAA.Preparation and Evaluation of Oroslippery Tablets Contain Irbesartan and Hydrochlorothiazide Combination.
46-Jain KK.An Overview of Drug Delivery Systems.Methods Mol Biol.2020.2059(1-54.
47-Belayneh A, Tadese E, Molla FJIJoGM.Safety and biopharmaceutical challenges of excipients in off-label pediatric formulations.2020.1051-66.
48-Domingues C, Jarak I, Veiga F, Dourado M, Figueiras A.Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.Pharmaceutics.2023.15(10).Pp:2431.
49- Khong YM, Liu J, Cook J, Purohit V, Thompson K, Mehrotra S, Cheung SA, Hay JL, Fletcher EP, Wang J, Sachs HC. Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019. European journal of pharmaceutics and biopharmaceutics. 2021 Jul 1;164:66-74.
50-Bensid A, El Abed N, Houicher A, Regenstein JM, Özogul F.Antioxidant and antimicrobial preservatives: Properties, mechanism of action and applications in food - a review.Crit Rev Food Sci Nutr.2022.62(11).Pp:2985-3001.
51-Ivanovska V, Rademaker CM, van Dijk L, Mantel-Teeuwisse AK.Pediatric drug formulations: a review of challenges and progress.Pediatrics.2014.134(2).Pp:361-72.
52-Rouaz K, Chiclana-Rodriguez B, Nardi-Ricart A, Sune-Pou M, Mercade-Frutos D, Sune-Negre JM, et al.Excipients in the Paediatric Population: A Review.Pharmaceutics.2021.13(3).Pp:387.
53-Nankar M, Walimbe H, Ahmed Bijle MN, Kontham U, Kamath A, Muchandi S.Comparative evaluation of cariogenic and erosive potential of commonly prescribed pediatric liquid medicaments: an in vitro study.J Contemp Dent Pract.2014.15(1).Pp:20-5.
54-Attebäck M, Hedin B, Mattsson S.Formulation Optimization of Extemporaneous Oral Liquids Containing Naloxone and Propranolol for Pediatric Use.2022.90(1).Pp:15.
55-Saadallah MN, Almajidi YQ, Ali AJA-RJoMS.Binary Ethosomal Gel for Enhanced Transdermal Delivery of Tazarotene: Development, Refinement, in vitro Evaluation, and Skin Penetration Investigations.2023.5(1S).Pp:S42-50.
56- Gleeson JP, Fein KC, Whitehead KA. Oral delivery of peptide therapeutics in infants: Challenges and opportunities. Advanced drug delivery reviews. 2021 Mar 25;173:112.
57- Abdelhakim HE, Coupe A, Tuleu C, Edirisinghe M, Craig DQ. Utilising co-axial electrospinning as a taste-masking technology for paediatric drug delivery. Pharmaceutics. 2021 Oct 12;13(10):1665.
58-Musakhanian J, Rodier JD, Dave M.Oxidative Stability in Lipid Formulations: a Review of the Mechanisms, Drivers, and Inhibitors of Oxidation.AAPS PharmSciTech.2022.23(5).Pp:151.
59- Ioniuc IK, Lupu A, Dragan F, Tarnita I, Alexoae MM, Streanga V, Mitrofan C, Thet AA, Nedelcu AH, Salaru DL, Burlea SL. Oxidative stress and antioxidants in pediatric asthma’s evolution and management. Antioxidants. 2024 Oct 31;13(11):1331.
60-Vangara KK, Yellepeddi VK. Excipients in Pediatric Formulations: Biopharmaceutical and Toxicological Considerations. In: Narang AS, Boddu SHS, editors. Excipient Applications in Formulation Design and Drug Delivery. Cham: Springer International Publishing; 2015. p. 497-519.
61-Mora MR, Dando R.The sensory properties and metabolic impact of natural and synthetic sweeteners.Compr Rev Food Sci Food Saf.2021.20(2).Pp:1554-83.
62-Gasmi Benahmed A, Gasmi A, Arshad M, Shanaida M, Lysiuk R, Peana M, et al.Health benefits of xylitol.Appl Microbiol Biotechnol.2020.104(17).Pp:7225-37.
63-Hu J, Fitaihi R, Abukhamees S, Abdelhakim HE.Formulation and Characterisation of Carbamazepine Orodispersible 3D-Printed Mini-Tablets for Paediatric Use.Pharmaceutics.2023.15(1).Pp:250.
64-Orlu M, Salunke S, Tuleu C.Paediatric pharmaceutics—the science of formulating medicines for children.2018.
65-Narang AS, Boddu SH. Excipient Applications in Formulation Design and Drug Delivery. In: Narang AS, Boddu SHS, editors. Excipient Applications in Formulation Design and Drug Delivery; Cham: Springer International Publishing; 2015. p. 1-10.
66-Suksawat T, Brniak W, Łyszczarz E, Wesoły M, Ciosek-Skibińska P, Mendyk A. Orodispersible dosage forms with rhinacanthin-rich extract as a convenient formulation dedicated to pediatric patients. Pharmaceuticals. 2024 Jul 27;17(8):994.
67-Bhalani DV, Nutan B, Kumar A, Singh Chandel AKJB.Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics.2022.10(9).Pp:2055.
68-Kriegel C, Festag M, Kishore RSK, Roethlisberger D, Schmitt G.Pediatric Safety of Polysorbates in Drug Formulations.Children (Basel).2019.7(1).Pp:1.
69-Bobillot M, Delannoy V, Trouillard A, Kinowski JM, Sanchez-Ballester NM, Soulairol I.Potentially Harmful Excipients: State of the Art for Oral Liquid Forms Used in Neonatology and Pediatrics Units.Pharmaceutics.2024.16(1).Pp:119.
70-Hoffman AC, Salgado RV, Dresler C, Faller RW, Bartlett CJTc.Flavour preferences in youth versus adults: a review.2016.25(Suppl 2).Pp:ii32-ii9.
71-Golhen K, Buettcher M, Kost J, Huwyler J, Pfister M.Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children.Pharmaceutics.2023.15(4).Pp:1033.
72-Pereira M, Silva FC, Simões S, Ribeiro HM, Almeida AJ, Marto J.Innovative, Sugar-Free Oral Hydrogel as a Co-administrative Vehicle for Pediatrics: a Strategy to Enhance Patient Compliance.AAPS PharmSciTech.2022.23(4).Pp:107.
73-Belayneh A, Tadese E, Molla F.Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations.Int J Gen Med.2020.13(1051-66.
74- Pezik E, Gulsun T, Sahin S, Vural I. Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate. European Journal of Pharmaceutical Sciences. 2021 Jan 1;156:105597.
75-Wang K, Jiang K, Wei X, Li Y, Wang T, Song Y.Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.AAPS PharmSciTech.2021.22(6).Pp:208.
76-Vallabh M. Evaluation of Salivary pH, Flow Rate and Buffer Capacity in Children with Protein Energy Malnutrition-A Comparative Study: Rajiv Gandhi University of Health Sciences (India); 2016.
77-Hidas A, Noy AF, Birman N, Shapira J, Matot I, Steinberg D, et al.Oral health status, salivary flow rate and salivary quality in children, adolescents and young adults with ADHD.Arch Oral Biol.2011.56(10).Pp:1137-41.
78-Kaguelidou F, Kassai Koupai B, Durrieu G.Pediatric pharmacology.Therapie.2018.73(2).Pp:111-2.
79-LUSCOMBE DK, NICHOLLS PJ. Processes of drug handling by the body. Smith and Williams' Introduction to the Principles of Drug Design and Action: CRC Press; 2019. p. 1-27.
80-Chapron BD, Chapron A, Leeder JS.Recent advances in the ontogeny of drug disposition.Br J Clin Pharmacol.2022.88(10).Pp:4267-84.
81-Juárez-Hernández JE, Carleton BC.Paediatric oral formulations: Why don't our kids have the medicines they need?Br J Clin Pharmacol.2022.88(10).Pp:4337-48.
82-Pildes RS, Blumenthal I, Ebel A.Stomach emptying in the newborn.Pediatrics.1980.66(3).Pp:482-3.
83- Mehta V, Hopson PE, Smadi Y, Patel SB, Horvath K, Mehta DI. Development of the human pancreas and its exocrine function. Frontiers in pediatrics. 2022 Sep 29;10:909648.
84-McNamara PJ, Alcorn J.Protein binding predictions in infants.AAPS PharmSci.2002.4(1).Pp:E4.
85-Talevi A, Bellera CL. Drug Binding to Tissue Components. The ADME Encyclopedia; Cham: Springer International Publishing; 2021. p. 1-9.
86- Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clinical pharmacokinetics. 2015 Dec;54:1183-204.
87- Mura P, Maestrelli F, D’Ambrosio M, Luceri C, Cirri M. Evaluation and comparison of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations. Pharmaceutics. 2021 Mar 24;13(4):437.
88-Ogbonna JDN, Cunha E, Attama AA, Ofokansi KC, Ferreira H, Pinto S, et al.Overcoming Challenges in Pediatric Formulation with a Patient-Centric Design Approach: A Proof-of-Concept Study on the Design of an Oral Solution of a Bitter Drug.Pharmaceuticals (Basel).2022.15(11).Pp:1331.
89-Langer C, Diaz DA, Van Alstine L, Bandi N, Fitzgerald S, Colgan S.Analysis of the Regulatory Divergence of Comparative Dissolution Requirements for Post-Approval Manufacturing Changes of Modified Release Solid Oral Dosage Forms.AAPS J.2019.22(1).Pp:2.
90- Tan DC, Khong YM, Mount S, Galella E, Mitra B, Charlton S, Kuhli M, Ternik R, Walsh J, Rajapakshe A, Thompson K. Pediatric formulation development–Challenges of today and strategies for tomorrow: Summary report from M− CERSI workshop 2019. European Journal of Pharmaceutics and Biopharmaceutics. 2021 Jul 1;164:54-65.
91- Cheung SY, Hay JL, Lin YW, de Greef R, Bullock J. Pediatric oncology drug development and dosage optimization. Frontiers in Oncology. 2024 Jan 29;13:1235947.
92-Chiaruttini G, Felisi M, Bonifazi DJTMoCTRI.Challenges in paediatric clinical trials: How to Make It Feasible.2018.Pp:11-33.
93-Shonkoff JP, Richter L, Van Der Gaag J, Bhutta ZAJP.An integrated scientific framework for child survival and early childhood development.2012.129(2).Pp:e460-e72.
94- Khan D, Kirby D, Bryson S, Shah M, Mohammed AR. Paediatric specific dosage forms: Patient and formulation considerations. International journal of pharmaceutics. 2022 Mar 25;616:121501.
95-Mahmood SZ, Yousif NZ, Salman ZDJAMJoPS.Types of Attractive Dosage Forms for Primary School Students and Associated Factors in Baghdad/Iraq.2020.20(4).Pp:13-22.
96-Almajidi YQ, Albadri AA, Jwaid MMJMJfMS.Utilization of semiconductor nanocrystals in cancer diagnose and treatment.2023.2(4).Pp:5.
97-Ernest TB, Craig J, Nunn A, Salunke S, Tuleu C, Breitkreutz J, et al.Preparation of medicines for children - a hierarchy of classification.Int J Pharm.2012.435(2).Pp:124-30.
98-Richey RH, Craig JV, Shah UU, Ford JL, Barker CE, Peak M, et al.The manipulation of drugs to obtain the required dose: systematic review.J Adv Nurs.2012.68(9).Pp:2103-12.
99-Fabiano V, Mameli C, Zuccotti GV.Paediatric pharmacology: remember the excipients.Pharmacol Res.2011.63(5).Pp:362-5.
100-Baguley D, Lim E, Bevan A, Pallet A, Faust SN.Prescribing for children - taste and palatability affect adherence to antibiotics: a review.Arch Dis Child.2012.97(3).Pp:293-7.
101-Hu S, Liu X, Zhang S, Quan D.An Overview of Taste-Masking Technologies: Approaches, Application, and Assessment Methods.AAPS PharmSciTech.2023.24(2).Pp:67.
102- Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clinical pharmacokinetics. 2014 Apr;53:327-46.
103-Ryu GS, Lee YJ.Analysis of liquid medication dose errors made by patients and caregivers using alternative measuring devices.J Manag Care Pharm.2012.18(6).Pp:439-45.
104-Yin HS, Mendelsohn AL, Wolf MS, Parker RM, Fierman A, van Schaick L, et al.Parents' medication administration errors: role of dosing instruments and health literacy.Arch Pediatr Adolesc Med.2010.164(2).Pp:181-6.
105-Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA.Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases.Expert Opin Drug Deliv.2012.9(3).Pp:303-23.
106- World Health Organization. Development of paediatric medicines: points to consider in formulation. WHO technical report series. 2012;790.
107-Hill SR.Putting the priorities first: medicines for maternal and child health.Bull World Health Organ.2012.90(3).Pp:236-8.
108-Liu F, Ranmal S, Batchelor HK, Orlu-Gul M, Ernest TB, Thomas IW, et al.Formulation factors affecting acceptability of oral medicines in children.Int J Pharm.2015.492(1-2).Pp:341-3.
109- Vlad RA, Antonoaea P, Todoran N, Rédai EM, Bîrsan M, Muntean DL, Imre S, Hancu G, Farczádi L, Ciurba A. Development and evaluation of cannabidiol orodispersible tablets using a 23-factorial design. Pharmaceutics. 2022 Jul 14;14(7):1467.
110-Wang B, Yang L, Wang B, Luo C, Wang Y, Wang H, et al.Development, In Vitro and In Vivo Evaluation of Racecadotril Orodispersible Films for Pediatric Use.AAPS PharmSciTech.2021.22(1).Pp:15.
111- Patel H, Raje V, Maczko P, Patel K. Application of 3D printing technology for the development of dose adjustable geriatric and pediatric formulation of celecoxib. International Journal of Pharmaceutics. 2024 Apr 25;655:123941.
112-Purandare S, Khot S, Avachat A."Fabrication of pellets via extrusion-spheronization for engineered delivery of Famotidine through specialized straws for Paediatrics".Ann Pharm Fr.2024.82(2).Pp:271-84.
113-Chachlioutaki K, Iordanopoulou A, Bouropoulos N, Meikopoulos T, Gika H, Ritzoulis C, et al.Pediatric and Geriatric-Friendly Buccal Foams: Enhancing Omeprazole Delivery for Patients Encountering Swallowing Difficulties.J Pharm Sci.2023.112(10).Pp:2644-54.
114-Singh D, Bedi N, Tiwary AK.Enhancing solubility of poorly aqueous soluble drugs: critical appraisal of techniques.Journal of Pharmaceutical Investigation.2017.48(5).Pp:509-26.
115- Salunke S, O'Brien F, Tan DC, Harris D, Math MC, Ariën T, Klein S, Timpe C. Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population. Advanced Drug Delivery Reviews. 2022 Nov 1;190:114507.
116- Frodsham M, Penton JA, inventors; Therakind Ltd, assignee. Methotrexate formulation. United States patent US 11,129,833. 2021 Sep 28.
117-Rautio J. Prodrugs. In: Offermanns S, Rosenthal W, editors. Encyclopedia of Molecular Pharmacology; Cham: Springer International Publishing; 2021. Pp:1257-63.
118-Franck B, Woillard JB, Theoret Y, Bittencourt H, Demers E, Briand A, et al.Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.Br J Clin Pharmacol.2021.87(8).Pp:3105-14.
119-He M, Zheng W, Wang N, Gao H, Ouyang D, Huang Z.Molecular Dynamics Simulation of Drug Solubilization Behavior in Surfactant and Cosolvent Injections.Pharmaceutics.2022.14(11).Pp:2366.
120-Polymersomes as Novel Drug Delivery Alternative to Conventional Liposomes.Al Mustansiriyah Journal of Pharmaceutical Sciences.2025.24(4).Pp:396-408.
121-Bedogni G, Garcia P, Seremeta K, Okulik N, Salomon C.Preformulation and Long-Term Stability Studies of an Optimized Palatable Praziquantel Ethanol-Free Solution for Pediatric Delivery.Pharmaceutics.2023.15(8).Pp:2050.
122-Pokhrel DR, Sah MK, Gautam B, Basak HK, Bhattarai A, Chatterjee A.A recent overview of surfactant-drug interactions and their importance.RSC Adv.2023.13(26).Pp:17685-704.
123-Elbardisy B, Boraie N, Galal S.Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization.Pharmaceutics.2022.14(12).Pp:2717.
124-Qasim Almajidi Y, Jawad AQ, Abdulameer Albadri A.Biocompatible PAMAM-PLGA-PCL Nanocarrier for Efficient Curcumin Delivery to Lung Cancer Cells: In Vitro Studies.Chem Biodivers.2024.21(10).Pp:e202401106.
125-Dahash RA, Rajab NA, Almajidi YQJIJDDT.Investigation of the effect of variable components on the preparation and in-vitro evaluation of lacidipine as an oral nanoemulsion dosage form.2021.11(3).Pp:1031-6.
126-Pınar SG, Oktay AN, Karaküçük AE, Çelebi N.Formulation Strategies of Nanosuspensions for Various Administration Routes.Pharmaceutics.2023 May 17;15(5) Pp:1520.
127-Perween N, Alshehri S, Easwari T, Verma V, Faiyazuddin M, Alanazi A, et al.Investigating the feasibility of mefenamic acid nanosuspension for pediatric delivery: Preparation, characterization, and role of excipients.2021.9(4).Pp:574.
128-Cirri M, Maestrelli F, Mennini N, Mannelli LD, Micheli L, Ghelardini C, Mura P. Development of a stable oral pediatric solution of hydrochlorothiazide by the combined use of cyclodextrins and hydrophilic polymers. International Journal of Pharmaceutics. 2020 Sep 25;587. Pp:119692.
129-Cirri M, Mura P, Benedetti S, Buratti S.Development of a Hydroxypropyl-beta-Cyclodextrin-Based Liquid Formulation for the Oral Administration of Propranolol in Pediatric Therapy.Pharmaceutics.2023.15(9).Pp:2217.
130- Hashim GM, Hameed GS, Hanna DB. The possible techniques that used to improve the bioavailablity, pharmacological activity, solubility and permeability of anti-viral drugs: Insight for COVID-19 antiviral drugs. AJPS. 2023 Jul 20;Pp:231.
131- Virtanen AA, Myślińska M, Healy AM, Power E, Madi A, Sivén M. The challenge of downstream processing of spray dried amorphous solid dispersions into minitablets designed for the paediatric population–A sustainable product development approach. European Journal of Pharmaceutical Sciences. 2024 May 1;196. Pp:106752.
132-Frenck RW, Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al.Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.N Engl J Med.2021.385(3).Pp:239-50.
133-Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al.Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med.2018.378(5).Pp:439-48.
134-Luo S, Ran M, Luo Q, Shu M, Guo Q, Zhu Y, et al.Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial.Paediatr Drugs.2017.19(5).Pp:479-86.
135- Płoszczuk A, Bosheva M, Spooner K, McIver T, Dissanayake S. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial. Therapeutic advances in respiratory disease. 2018 May 31;12:1753466618777924.
136-Schwartz S, Correll CU.Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.J Am Acad Child Adolesc Psychiatry.2014.53(2).Pp:174-87.
137- Almajidi YQ, Muslim RK. Oligonucleotides as a Novel Therapeutic Approach: An Innovative Area for Drug Delivery in Neurological Disorders. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2025 Jan 14;25(1).Pp:143-69.
138-de Figueiredo ACM. Real-world effectiveness of gene therapy Zolgensma®(Onasemnogene Abeparvovec-xioi) for the treatment of Spinal Muscular Atrophy (SMA): Universidade de Lisboa (Portugal); 2021.
139-Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, et al.Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.J Clin Endocrinol Metab.2022.107(7).Pp:e2717-e28.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mays Fadhil Mohammed-Kadhum , Ghaidaa S. Hameed , Zainab H. Mahdi
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
